NIVOPOSTOP (GORTEC 2018-01): Ph3 RCT of adjuvant nivolumab added to radio-chemotherapy in Pts w/ resected head & neck squamous cell carcinoma at high risk of relapse - Bourhis et al. #ASCO25 LBA2 meetings.asco.org/abstracts-pr... #NCT03576417 #hncsm #ImmunoOnc
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
April 23, 2025 at 7:20 PM
NIVOPOSTOP (GORTEC 2018-01): Ph3 RCT of adjuvant nivolumab added to radio-chemotherapy in Pts w/ resected head & neck squamous cell carcinoma at high risk of relapse - Bourhis et al. #ASCO25 LBA2 meetings.asco.org/abstracts-pr... #NCT03576417 #hncsm #ImmunoOnc